Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database

Background: Biologics play an important role in the treatment of moderate to severe Crohn’s disease (CD). Ustekinumab was approved for such patients in the Republic of Korea on 1 December 2018. Therefore, we need to compare the efficacy of ustekinumab and anti-TNF inhibitors. Methods: We compared on...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Gi Hyeon, Jung, Sung Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056835/
https://www.ncbi.nlm.nih.gov/pubmed/36983396
http://dx.doi.org/10.3390/jcm12062397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056835/
https://www.ncbi.nlm.nih.gov/pubmed/36983396
http://dx.doi.org/10.3390/jcm12062397

Ejemplares similares